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Abstract 
Aim: Second-generation basal insulin analogues (e.g. insulin degludec, insulin glargine 300 
U/mL), were designed to further extend the duration of insulin action and reduce within-day 
and day-to-day variability, and consequently hypoglycaemia risk, versus earlier long-acting 
basal insulins. This review examines the pharmacokinetic/pharmacodynamic characteristics 
of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL), and their influence 
on clinical outcomes. 
Methods: Available pharmacokinetic/pharmacodynamic publications comparing insulin 
degludec and insulin glargine were reviewed. 
Results: Both insulin degludec and insulin glargine 300 U/mL have more prolonged and stable 
pharmacokinetic/pharmacodynamic profiles than the earlier basal insulin analogue, insulin 
glargine 100 U/mL. Insulin glargine 300 U/mL (0.4 U/kg, morning) showed a more stable 
pharmacodynamic profile (20% lower within-day variability [p=0.047]) and more even 24-h 
distribution (over each 6-h quartile) than insulin degludec 100 U/mL, whereas the 
supratherapeutic 0.6 U/kg dose demonstrated a similar, albeit non-significant, trend. In 
contrast, a second clamp study indicated lower day-to-day variability in the 24-h glucose-
lowering effect (variance ratio 3.70, p<0.0001), and more even dosing over each 6-h quartile, 
with insulin degludec 200 U/mL versus insulin glargine 300 U/mL (0.4 U/kg, evening). 
Methodological differences and differences in bioequivalence that may explain these 
discrepancies are discussed. 
Conclusions: Compared with earlier insulin analogues, second-generation basal insulins have 
improved pharmacokinetic/pharmacodynamic profiles that translate into clinical benefits, 
primarily reduced nocturnal-hypoglycaemia risk. Additional head-to-head comparisons of 
insulin degludec and insulin glargine 300 U/mL at bioequivalent doses, utilising continuous 
glucose monitoring and/or real-world evidence, are required to elucidate the differences in 
their pharmacological and clinical profiles. 
Keywords: basal insulins, insulin glargine, insulin degludec, hypoglycaemia 
Abbreviations: AUCGIR,τ,SS, steady-state area under the GIR curve for one dosing period; CGM, 
continuous glucose monitoring; GIR, glucose infusion rate; GIR-AUC, area under the GIR curve; 
Gla-100, insulin glargine 100 U/mL; Gla-300, insulin glargine 300 U/mL; IDeg, insulin degludec; 
INS, insulin concentration; INS-Cmax, maximum INS; NPH, neutral protamine Hagedorn; PD, 
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pharmacodynamic; PK, pharmacokinetic; PTF, peak-to-trough fluctuation; T1DM, type 1 
diabetes; T2DM, type 2 diabetes  
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Introduction 
Since the time basal insulins were first developed, there have been ongoing attempts to 
produce formulations with more prolonged and/or flatter pharmacokinetic (PK) and 
pharmacodynamic (PD) profiles over 24 h that better mimic the low and constant physiological 
basal insulin secretion seen in the fasting state in healthy subjects [1]. Fluctuations in plasma 
insulin concentration (INS) during the day (within-day variability) and between days (day-to-
day variability) can result in variable plasma glucose control, which may expose individuals to 
periods of hyper- or hypoglycaemia [2]. Insulins with flatter PK profiles (less pronounced peaks 
and troughs of insulin exposure) and a lower within-day and day-to-day variability will 
therefore result in a more consistent metabolic action and reduced risk of hypoglycaemia [3]. 
In turn, this may give individuals and healthcare professionals the confidence to titrate the 
insulin dose more confidently, which can help achieve glycaemic targets, with a degree of 
flexibility in the timing of administration. 
Variations in insulin bioavailability can be assessed using PK endpoints, [4] which are generally 
considered to be a more specific measure of “intrinsic” variability of the tested insulin 
preparation. PD endpoints reflect insulin action that can be influenced by within-day and day-
to-day differences in insulin sensitivity of individual subjects in their real life [4,5]. Euglycaemic 
clamp studies are used to assess both PK and insulin action (PD), the latter by determining the 
glucose infusion rate (GIR), which gives a quantitative evaluation of the biological effect of 
injected insulin. With therapeutic doses of basal insulin, the GIR primarily reflects the 
suppression of hepatic glucose production rather than increase in insulin-mediated glucose 
uptake, if any [5,6]. The area under the GIR curve (GIR-AUC) therefore provides information 
on blood glucose-lowering effect over a given time interval.  
Insulin glargine 100 U/mL (Gla-100), a first-generation long-acting basal insulin analogue, 
enables glycaemic control to be achieved with once-daily dosing in most people with diabetes 
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[7,8], with a lower risk of hypoglycaemia compared with earlier basal insulin preparations such 
as neutral protamine Hagedorn (NPH) insulin [9-12] and Lente insulin [13,14]. However, the 
more recent second-generation basal insulin analogues, such as insulin glargine 300 U/mL 
(Gla-300) and insulin degludec (IDeg-100 or -200 U/mL [IDeg-100 or IDeg-200]), when 
compared with Gla-100, have a flatter profile, more prolonged duration of action over 24 h 
and reduced variability, thus approaching the goal of a more physiological basal insulin, with 
a lower risk of hypoglycaemia [15-17]. The aim of this publication is to review the available 
PK/PD data for IDeg-100 or IDeg-200 and Gla-300 in people with diabetes and assess how 
these may impact on clinical outcomes, such as the risk of hypoglycaemia and the flexibility of 
dose administration. 
The PK/PD profiles of Gla-300, Gla-100 and IDeg-100 or -200 
Gla-300 versus Gla-100 
Mechanisms of protraction of insulin glargine (Gla-300 and Gla-100) 
Insulin glargine (both Gla-100 and Gla-300) differ from human insulin through the substitution 
of glycine for asparagine at A21 and the retention of two arginine molecules at position B30 
[3,15]. The former change ensures stability of the insulin molecule, while the latter is pivotal 
to shift the isoelectric point [18]. This latter change makes insulin glargine soluble at acidic pH 
in the vial or pen cartridge, but following administration it precipitates amorphously at the 
neutral pH of the subcutaneous tissue, thus delaying absorption of its active metabolite M1 
(A21-Gly-human insulin), formed following the rapid removal of the B-chain terminal di-
arginine molecules by subcutaneous proteases [18,19]. The maximum plasma concentration 
of M1 occurs at approximately 12 h post injection, with exposure enduring for 24 h and 
beyond [19-21]. By concentrating insulin glargine to a third of its volume (from 100 U/mL to 
300 U/mL), the surface area of the subcutaneous precipitate is reduced by half [22], thereby 
slowing its dissolution and consequently its absorption from the subcutaneous tissue, 
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resulting in Gla-300 having a more prolonged and flatter PK/PD proﬁle than Gla-100 [23]. 
Owing to the longer time Gla-300 remains in the subcutaneous tissue prior to release of 
dimers and monomers, partial degradation by tissue proteases takes place so that ultimately 
not all of the injected Gla-300 reaches the circulatory system. In fact, the clinical dose of the 
less bioavailable Gla-300 is greater than that of Gla-100 [24-27] and ensures PK/PD 
bioequivalence with Gla-100 while maintaining the flatter and more evenly distributed PK/PD 
profile [6]. 
Key studies that assessed PK/PD differences between Gla-300 and Gla-100 
Single-dose studies 
Shiramoto et al, 2015 conducted a single dose study of Gla-300 (0.4, 0.6 and 0.9 U/kg [0.9 
U/kg only used in the European cohort]) or Gla-100 (0.4 U/kg) in Japanese (n=18) and 
European (n=24) participants with type 1 diabetes (T1DM) [28]. Exposure and metabolic 
effects were more prolonged and evenly distributed over 24 h with Gla-300 compared with 
Gla-100 at the 0.4 U/kg dose, with a delayed onset of measurable metabolic effects with 
Gla-300 [28], due to the prolongation of dissolution of the subcutaneous depot, an 
observation provided uniquely from single-dose studies. However, the clinical applicability of 
single-dose studies is relatively limited, as they do not reflect steady-state conditions following 
repeated daily injections, as occurs in the real lives of people with diabetes. 
Steady-state PK/PD studies 
Various euglycaemic clamp studies have assessed the steady-state PK/PD of Gla-300 versus 
Gla-100 in people with diabetes (Table 1). While these studies have some similarities in their 
study designs (insulin dose and participant populations), they also have important differences 
(time of dosing, length of clamp and the use of unsmoothed versus smoothed GIR profiles to 
calculate variability), which will be explored in more detail in this section. These study design 
differences may help to explain some of the differing results obtained from these studies.  
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Becker at al, 2015 performed a randomised, double-blind, crossover study involving 30 
individuals with T1DM that compared the PK/PD profiles of fixed doses of Gla-300 and Gla-
100 [23]. One cohort (n=18) received 0.4 U/kg of Gla-300 during the first 8-day treatment 
period followed by 0.4 U/kg Gla-100 in the second 8-day treatment period, or vice versa. A 
second cohort (n=12) received 0.6 U/kg of Gla-300 or 0.4 U/kg of Gla-100 during the first 8-
day treatment period, and crossed over to the alternative treatment during the second 8-day 
treatment period. Basal insulins were administered once daily in the evening. The dose on Day 
8 of each treatment period was followed by a 36-h euglycaemic clamp. The steady-state INS 
and GIR profiles of Gla-300 were more constant, prolonged and more evenly distributed over 
the 24-h period when compared with Gla-100 (Figure 1A and 1B). Blood glucose control (≤5.8 
mmol/L [≤105 mg/dL]) was maintained for approximately 5 h longer with Gla-300 (median 30 
h) versus Gla-100 (median 25 h) at the 0.4 U/kg/day dose. This study also showed that identical 
doses of Gla-300 and Gla-100 result in lower 24-h plasma INS and glucose-lowering activity 
with Gla-300 versus Gla-100. 
In a second study by Becker et al, in 2015, the steady-state variability of Gla-300 (with or 
without polysorbate-20) was assessed in a population of 50 individuals with T1DM. The study 
included two 24-h euglycaemic clamps using the Biostator™ device, following 6 consecutive 
days of once-daily administration of 0.4 U/kg Gla-300 [29]. As there was PK/PD bioequivalence 
between Gla-300 with and without polysorbate-20, Becker et al reported that this allowed 
variability to be calculated for the overall population. The within-day variability in insulin 
action, calculated based on unsmoothed GIR, was low, with a median (interquartile range 
[IQR]) peak-to-trough ratio (PTR) of 1.8 (1.5–2.1) and a median (IQR) peak-to-trough 
fluctuation (PTF) of 0.6 (0.4–0.7). PTR is calculated by dividing the maximum insulin 
concentration by the minimum insulin concentration. PTF is calculated by subtracting the 
minimum from the maximum insulin concentration and dividing by the average insulin 
concentration. Day-to-day (within-subject) variability (coefficient of variation [CV]) in insulin 
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exposure was 17.4% for INS-AUC0–24 and 33.4% for maximum INS (INS-Cmax). Median 
fluctuation in unsmoothed GIR (within-day variability) was 1.0 (IQR 0.8–1.1) mg/kg/min, with 
a PD variability of 34.9% for GIR-AUC0–24.  
More recently Porcellati, Lucidi and colleagues reported  results from a randomised, single-
blind, two-way crossover euglycaemic clamp study of Gla-300 versus Gla-100 in people with 
T1DM (N=18), using individualised clinical doses of the two insulins [6,30]. The participants, 
previously receiving Gla-100 as basal insulin, were randomised to either Gla-300 or Gla-100 
for 3 months, and then after 2 months of washout were crossed-over to the other basal insulin 
for a further 3-month period. The basal insulin was titrated to achieve a fasting plasma glucose 
level of 5.0–6.1 mmol/L (90–110 mg/dL). At the end of each 3-month period a 24-h 
euglycaemic clamp was performed following evening subcutaneous dosing of the basal insulin 
under investigation, at the dose used by each individual. The mean (± SD) doses used were 
0.35 ± 0.08 U/kg for Gla-300 and 0.28 ± 0.07 U/kg for Gla-100, both maintaining plasma 
glucose at 5.6 mmol/L (100 mg/dL) for 24 h. Steady-state plasma INS was lower with Gla-300 
versus Gla-100 during the first 6-h period (treatment ratio [Gla-300/Gla-100] 0.91 [90% CI: 
0.86–0.97]), but was higher for Gla-300 versus Gla-100 during the last 12-h period (1.38 [90% 
CI: 1.21–1.56]). Plasma glucose was maintained for 24 h with both Gla-300 and Gla-100 (100.5 
± 1.2 and 101.4 ± 1.8 mg/dL; 0.99 [90% CI: 0.98–1.0]). While the glucose infusion rate was 
similar with Gla-300 and Gla-100 over the entire 24-h study period (treatment ratio [Gla-
300/Gla-100] 1.03 [90% CI: 0.88–1.21]), it was lower with Gla-300 during the first 12 h (0.77 
[90% CI: 0.62–0.95]) and higher between 18 and 24 h when compared with Gla-100 (1.91 [90% 
CI: 1.37–2.68]). Hepatic glucose production was less suppressed on Gla-300 compared with 
Gla-100 for the initial 6 h, but more suppressed with Gla-300 versus Gla-100 over the last 6 h, 
suggesting more stable and prolonged insulin action with Gla-300 versus Gla-100 [6]. No 
between treatment difference in effect on peripheral glucose utilisation was observed. In 
addition, Gla-300 was more effective than Gla-100 in suppressing lipolysis and ketogenesis for 
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24 h [30], and glucagon concentration (data on file). It was concluded that despite equivalent 
glucose efficacy, Gla-300 modulates glucose metabolism more physiologically than Gla-100. 
The improved PK of Gla-300 was paralleled by improved PD (Figure 1C), explained by less 
suppression of hepatic glucose output at night and greater suppression in the afternoon 
versus Gla-100. 
Clinical relevance of the PK/PD profiles of Gla-300 and Gla-100 
The phase 3 EDITION clinical trial programme evaluated Gla-300 versus Gla-100 in participants 
with either type 2 diabetes (T2DM) or T1DM [17,24-27,31,32]. These studies demonstrated 
comparable glycaemic control with Gla-300 and Gla-100, together with a reduced risk of 
hypoglycaemia with Gla-300, predominantly, but not exclusively, at night and despite a higher 
Gla-300 dose in T2DM [17,24,26,27,31,32]. In T1DM, hypoglycaemia was similar between Gla-
300 and Gla-100 [25], except for nocturnal conﬁrmed (≤3.9 mmol/L [≤70 mg/dL]) or severe 
hypoglycaemia in the first 8-weeks of the study (the period during which the largest increase 
in insulin dose during titration was observed), which was lower with Gla-300 versus Gla-100 
(risk ratio 0.69 [95% CI 0.53–0.91]) [25]. The final dose of Gla-300 required to match the effects 
of Gla-100 was consistently higher in the EDITION studies [24,26,27,31,32]. The requirement 
for a higher dose of Gla-300 versus Gla-100 was expected, due to the previously mentioned 
local degradation of Gla-300 at the injection site and consequently lower bioavailability 
compared with Gla-100. 
These findings have been confirmed in continuous glucose monitoring (CGM) studies. 
Jinnouchi et al, 2015 conducted a CGM study in 20 Japanese participants with T1DM and 
demonstrated a slightly lower glucose variability over 24 h, and at night, with Gla-300 versus 
Gla-100 (administered once daily at bedtime), and a trend towards fewer participants 
experiencing confirmed or severe hypoglycaemic events with Gla-300 [33]. Bergenstal et al, 
2017, reported another CGM study in 59 participants with T1DM showed less variation in the 
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mean 24-h glucose curves with Gla-300 compared with Gla-100 [34]. In this study, the glucose 
profiles with Gla-300 did not differ between morning and evening injection, whereas with Gla-
100 the morning injection was associated with more pronounced peaks and troughs of insulin 
activity than when Gla-100 was administered in the evening. Finally, this study also showed a 
significantly lower rate of nocturnal (00:00–05:59 h) confirmed (<3.0 mmol/L [<54 mg/dL]) or 
severe hypoglycaemia with Gla-300 versus Gla-100.  
IDeg-100 and IDeg-200 versus Gla-100 
Mechanisms of protracted exposure with insulin glargine and IDeg 
IDeg, the second-generation acylated insulin after insulin detemir, has a different mode of 
protraction to glargine (Gla-100 and Gla-300), resulting from the removal of threonine from 
position B30, and the addition of a 16-carbon fatty diacid via a glutamic acid spacer at B29. In 
pharmaceutical formulation in the presence of phenol and zinc, IDeg forms highly stable di-
hexamers. After injection, the rapid phenol depletion results in multi-hexamer formation at 
the injection site. Thereafter, the gradual diffusion of zinc leads to dissociation of the multi-
hexamer chains to release monomers, which are absorbed into the systemic circulation. The 
gradual break-up of the IDeg multi-hexamer chains results in a protracted release of insulin 
from the subcutaneous depot without precipitation. In the systemic circulation, IDeg binds to 
albumin before being released into the extracellular space, and circulates in blood largely 
bound to albumin until it is released for its binding at insulin receptor sites. The two IDeg 
formulations, Deg-100 and IDeg-200, appear to be bioequivalent [35], but it is possible that 
there are minor differences in PK/PD characteristics between the two IDeg formulations. 
Key studies that define PK/PD differences between IDeg and Gla-100 
Two euglycaemic clamp studies comparing IDeg-100 with Gla-100 have been conducted 
(Table 1) [36,37]. In 2015, Heise et al, demonstrated that the mean 24-h GIR profiles were 
flatter and more stable for IDeg-100 versus Gla-100, at doses of 0.4, 0.6 or 0.8 U/kg 
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administered once daily in the evening [37]. At steady state, variability in PK (serum insulin 
levels) and PD (GIR) was lower for IDeg-100 versus Gla-100. However, one should note that, 
in contrast to glargine, which allows measurement of the free, active insulin in serum,  with 
IDeg the interpretation of PK is limited because it is not possible to measure the “free” active 
serum IDeg concentration, but only the total concentration (albumin-bound + free fraction).. 
In 2012, Heise et al reported that the day-to-day CV in glucose-lowering effect (AUCGIR,0–24,SS; 
main endpoint) was 20% for IDeg-100 and 82% for Gla-100 at a dose of 0.4 U/kg administered 
once daily in the evening [36]. However, in addition to the complexity of the experimental 
procedure, the data of Heise et al, 2012 have not been confirmed by clinical observations and 
may not be representative of clinical practise. A CGM study by Yamamoto et al, 2016 has 
reported higher within-day glucose variability for Gla-100 versus IDeg-100 using the measure 
mean amplitude of glucose excursions (MAGE), which was 144.4 and 121.7 mg/dL for Gla-100 
and IDeg-100 over 24 h (1.2 fold difference) [38]. In clinical studies reporting the day-to-day 
variability in fasting plasma glucose, some have reported no difference [39], whilst another 
study has reported significantly lower day-to-day variability in fasting plasma glucose with 
IDeg-100 versus Gla-100 [40]. Higher variability in AUC-GIRtotal (48% vs 27%, p<0.001) and 
GIRmax (36% vs 23%, p<0.001) was reported by Heise et al, 2004, for Gla-100 vs insulin detemir 
[41], respectively, a finding again not supported by clinical studies [42,43]. It is not known why 
variability is so high for Gla-100 in the Heise et al, 2004 study; variability was calculated as the 
square-root of the within-subject variance using logarithmically transformed end points, 
whereas other studies calculate variability by dividing the standard deviation of a value by the 
mean [41]. The authors also speculated that the infusion of human insulin at the start of the 
glucose clamp potentially affected the variability of Gla-100 more than insulin detemir, as the 
variability of the GIR data was particularly marked in the first two-hours of the clamp for Gla-
100 but not insulin detemir [41], a comment which may imply methodological problems with 
the experiments. Interestingly, the same investigators, using the same methodology, were not 
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able to confirm their own data, and reported a nearly twice different variability in 24-h glucose 
lowering for the same dose of Gla-100 in T1DM, i.e. 48% in 2004, but 82% in 2012 [36,41]. 
Clinical relevance of the PK/PD profiles of IDeg and Gla-100 
In clinical studies in people with T2DM, the mean HbA1c reductions were similar for IDeg-100 
or IDeg-200 compared with Gla-100, which is unsurprising given the treat-to-target design 
[39,44], although fasting plasma glucose was consistently lower with IDeg-100 or IDeg-200. In 
the BEGIN Once Long study in 1030 insulin-naïve people with T2DM, IDeg-100 was associated 
with lower rates of nocturnal confirmed (<3.1 mmol/L [<56 mg/dL]) or severe hypoglycaemia 
(0.27 vs 0.46 episodes/patient-year, p=0.002) and anytime severe hypoglycaemia (0.006 vs 
0.021 episodes/patient-year, p=0.023) than Gla-100 [44]. Similar results were seen in the 
DEVOTE study (n=7637), which showed a significant reduction in severe hypoglycaemia rates 
with IDeg-100 compared with Gla-100 (3.70 vs 6.25 episodes/patient-year, p<0.001) [45], and 
the SWITCH 2 study (n=721), which showed significant reduction in overall symptomatic 
hypoglycaemia that was confirmed by a blood glucose level <3.1 mmol/L (<56 mg/dL) or were 
severe (219.9 vs 275.1 episodes/100 patient-year, p<0.001) and at night (72.0 vs 88.4 
episodes/100 patient-year, p<0.001); although no significant differences in severe 
hypoglycaemia rates were observed in the SWITCH2 study, this may reflect the smaller 
participant population in SWITCH 2 versus BEGIN Once Long and DEVOTE [46]. However, in 
contrast, in the BEGIN Low Volume trial (n=460) comparing Gla-100 with IDeg-200 in insulin-
naïve people with T2DM, the rates of overall confirmed hypoglycaemia (defined as events 
with a blood glucose level of <3.1 mmol/L [<56 mg/dL]) or severe hypoglycaemia) of 1.42 and 
1.22 episodes/patient-year, respectively, and of nocturnal confirmed events (0.28 and 0.18 
episodes/patient-year, respectively) were not significantly different between the two basal 
insulins; this finding may again reflect the smaller participant population in this study versus 
SWITCH 2 and DEVOTE, and could still be of clinical significance [39]. In addition, FPG 
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reductions were significantly greater with IDeg-200 vs Gla-100 (23.7 vs. 23.4 mmol/L [–67 vs. 
–61 mg/dL]) (p=0.02) and insulin dosing was lower (0.53 versus 0.60 U/kg/d) [39]. 
In the BEGIN Basal-Bolus study in T1DM, Gla-100 and IDeg-100 treatment over a 2-year period 
were associated with similar reductions in HbA1c (treatment difference −0.04 %), not 
unexpected given the treat-to-target study design, with a lower rate of nocturnal confirmed 
(<3.1 mmol/L [<56 mg/dL]) or severe hypoglycaemia with IDeg-100 compared with Gla-100 
(3.9 vs 5.3 episodes/patient-year, p=0.02) [47]. Similar observations were made over 32-
weeks of treatment in the SWITCH 1 study in people with T1DM , with IDeg-100 showing 
significantly lower rates of confirmed (<3.1 mmol/L [<56 mg/dL]) or severe hypoglycaemia 
overall (2044.6 vs 2168.4 episodes/100 patient-year, p=0.002) and at night (281.2 vs 371.9 
episodes/100 patient-year, p<0.001) compared with Gla-100, as well as significantly lower 
rates of severe hypoglycaemia (86.8 vs 105.2 episodes/100 patient-year, p=0.003) [48]. 
Gla-300 versus IDeg-100 and IDeg-200 
Key studies that define PK/PD differences between Gla-300 and IDeg 
Gla-300 was compared directly with IDeg-100 in a euglycaemic clamp study by Bailey et al, 
2017, that assessed morning injection of both insulins (Table 1) [49]. This study was performed 
at Profil (Profil, Neuss, Germany), and consisted of two 8-day treatment periods with 
participants (N=48) receiving either Gla-300 or IDeg-100 (0.4 U/kg or 0.6 U/kg) once daily 
before breakfast in the first treatment period, and with the treatment assignment (Gla-300 or 
IDeg-100) reversed in the second treatment period. The basal insulin dose on Day 8 of each 
treatment period (morning dosing) was followed by a 30-h euglycaemic clamp using a 
ClampArt® device (Profil) [49]. The within-day variability of smoothed GIR (GIR-smFL0–24) (main 
endpoint) was significantly lower with Gla-300 than IDeg-100 at the 0.4 U/kg/day dose 
(treatment ratio Gla-300/IDeg-100: 0.80 [90% CI: 0.66–0.96], p=0.047) (LOESS smoothing 
factor 0.15), by comparing absolute differences in smoothed individual GIR versus mean 
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individual GIR over 24 h (Figure 2A). For the 0.6 U/kg/day dose the variability of smoothed GIR 
did not achieve statistical significance (treatment ratio 0.96 [90% CI 0.83 to 1.11]; p=0.603). 
The reason for this difference is not known. However, the 0.4 U/kg/day dose is the one 
clinically relevant for the majority of individuals with T1DM. Total GIR (GIR-AUC0-24) was 
approximately 14% higher with IDeg-100 versus Gla-300 (1947 and 1676 mg/kg, respectively), 
confirming the expected lower bioavailability of Gla-300 versus IDeg. Over 24 h, Gla-300 
exposure was also more evenly distributed in terms of the proportion of GIR-AUC0–24 in each 
6-h quartile compared with IDeg-100 for both the 0.4 and 0.6 U/kg/day doses (Figure 2B). 
Gla-300 provided steady-state plateau-like insulin profiles for up to 16 h post dose, followed 
by a subsequent slow decline (Figure 2C). The insulin-over-time curve for IDeg-100 increased 
steadily from the time of injection until a maximum concentration at 10 h after dosing, before 
showing a slow decline (Figure 2D), a profile consistent with that seen in other studies (Figure 
3) [37]. However, as already stated above, PK comparisons of IDeg and Gla-300 are limited, as 
it is not possible to specifically measure the “free” insulin component of IDeg [37], making the 
interpretation of PK studies comparing the acylated insulins IDeg and IDet with Gla-100 or Gla-
300 problematic [50]. 
A second clamp study was performed by the same investigators at Profil (Heise et al.) and 
compared the evening dosing of Gla-300 and IDeg-200 [51]. The study consisted of two 12-
day treatment periods with participants (N=57) receiving either Gla-300 or IDeg-200 (0.4 U/kg) 
once daily at approximately 20:00 h in the first treatment period and treatment assignment 
(Gla-300 or IDeg-200) being reversed in the second period. GIR and INS were determined over 
the 24-h euglycaemic clamps on Days 6, 9 and 12 of each treatment period. The methodology 
of the clamp and the automatic device used was identical to the study described above [49] 
as both studies were performed at the same site with the same investigators. The steady-state 
area under the GIR curve for one dosing period (AUCGIR,τ,SS) for Gla-300 was 30% lower than 
for IDeg-200 (estimated ratio Gla-300/IDeg-200: 0.70 [95% CI: 0.61–0.80], p<0.0001) 
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suggesting differential glucose metabolic effect by the same nominal doses of the two insulins. 
Under these conditions, a lower day-to-day variability in AUCGIR,τ,SS (main endpoint) was 
reported for IDeg-200 versus Gla-300 at 0.4 U/kg/day: variance ratio Gla-300/IDeg-200: 3.70 
(95% CI: 2.42–5.67) (around 4-fold difference with this variability parameter), although the 
variance values were not reported. The CV for day-to-day variability in glucose-lowering 
activity was 33% for IDeg-200 and 67% for Gla-300. The distribution of glucose-lowering 
activity (AUCGIR as a proportion of AUCGIR,τ,SS) across the 6-h quartiles of the 24-h dose period 
was more consistent for IDeg-200 than Gla-300. In post hoc analyses, in which absolute within-
day variability was converted to relative variability to account for the different potency of the 
study insulins, the relative within-day variability was 37% lower for IDeg-200 than Gla-300 
(estimated ratio IDeg-200/Gla-300: 0.63 [95% CI: 0.54–0.73], p<0.0001; absolute values not 
published). 
It is of interest that these two studies, as already said conducted by the same investigators 
and using an identical euglycaemic clamp technique, provide conflicting findings. The two 
studies evaluated individuals with T1DM, and their demographic characteristics (age, BMI, 
duration of diabetes, HbA1c and baseline insulin dose) were similar. In one study IDeg-100 was 
used [49], while IDeg-200 was used in the other [51]. In the former study, basal insulin was 
administered in the morning [49], while in the latter it was given in the evening [51]. Above 
all, the two studies had two different primary aims, i.e., assessing within-day variability in the 
former [49] and day-to-day variability in the latter [51]. Additionally, in both studies the 
euglycaemic clamp was not strictly euglycaemic as several subjects had an escape of blood 
glucose to hyperglycaemic values during the 24 h of the study (Figure 4A). Since the 
“variability”, either within-day or day-to-day, is calculated from excursions of GIR above or 
below a mean value over 24 h, if blood glucose increases above 5.5 mmol/L (100 mg/dL), the 
algorithm of the machine reduces and eventually stops glucose infusion, creating a fluctuation 
of GIR that contributes to variability. Thus, a strictly euglycaemic clamp (i.e. a study where 
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blood glucose is <5.5 mmol/L [100 mg/dL] over the full clamp period) will result in lower 
variability (both within-day as well as day-to-day) compared with another clamp study where 
blood glucose increases above 5.5 mmol/L (100 mg/dL) for several hours. As this 
hyperglycaemia occurred in more participants in the Heise et al study, and with larger glucose 
excursions in the Gla-300 versus the IDeg-200 group compared with the Bailey et al study 
(Figure 4) [49,51], the higher variability of Gla-300 in the Heise et al study is likely to be an 
artefact owing to failure to maintain euglycaemia in the clamp. This problem was predictable 
as Heise et al used identical insulin doses for Gla-300 and IDeg-200 and observed lower 
bioavailability (and therefore lower glucose metabolic effects with the same nominal dose) 
with Gla-300 versus IDeg-200 [51]. Taken together, these observations suggest that the 
important question of differences in variability between Gla-300 and IDeg has to be re-
assessed by future studies with doses reaching bioequivalent glucose metabolic effects for 
Gla-300 and IDeg. Finally, if Gla-300 is much more variable than IDeg, then one would expect 
to see a difference in glucose variability between treatment with Gla-300 versus IDeg (see 
below BRIGHT study [52]) . 
The recent comments by Reinhard Becker highlight, in detail, the several flaws and pitfalls of 
the Heise et al, 2017 study [51,53]. Among other critiques, Becker primarily underlines the 
fact that the day-to-day pharmacodynamic variability between Gla-300 and IDeg-200 was 
assessed in the presence of different glucose metabolic effects observed with the two insulins, 
i.e. there was a different effect of Gla-300 and IDeg-200 on total glucose metabolism (30% 
higher total GIR for IDeg). This implies a different effect of the two insulins on the suppression 
of hepatic glucose production and stimulation of peripheral glucose utilisation, suggesting that 
the use of GIR to assess variability under these conditions mixes the different effects of the 
two insulins in a spurious manner. On the other hand, in their most recent editorial [50], Heise 
et al reaffirm the validity of their original study, as well as its interpretation [37,50]. As 
indicated previously, day-to-day and within-day variability should be reassessed in a different 
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experimental model more closely representing the clinical situation, where different basal 
insulins are compared at different doses needed in individual subjects to match the glucose 
metabolic effect, as recently demonstrated [6]. 
Monnier et al, 2018, when considering the discrepancies between the findings of the two 
studies, questioned whether the euglycaemic clamp test is sufficiently reliable to detect small 
differences in PD between the insulin preparations [54]. The editorial noted several factors 
that might explain the reported differences, including the difficulty with the longer-acting 
analogues of starting the clamp without any residual insulin action from the previous insulin 
dose, the impact of hepatic glucose production as the insulin concentration falls towards the 
end of longer clamps of 24 h or longer and the fundamental difficulty in comparing Gla-300 
and IDeg owing to the albumin binding properties of IDeg [54].  
Finally, it should be noted that in both studies, variability was calculated based on smoothed 
GIR, which may differ markedly from unsmoothed raw data, as the smoothing algorithms used 
may have a major impact on the calculated variability [29]. Although the crossover design of 
these studies may balance out any effects on variability, the impact of such an approach 
relative to treatment is not known. 
A recent review by Heise et al [55] analysed pooled data from two PK/PD studies of IDeg versus 
Gla-100, and also commented on the study of IDeg-200 versus Gla-300 mentioned above [51]. 
This pooled post hoc analysis of Heise et al [55] indicated lower variability with IDeg-200 
versus Gla-300 after participants who achieved blood glucose >7.0 mmol/L during the clamp 
were excluded from the calculations. However, the cut-off point of 7.0 mmol/L was arbitrarily 
elevated as being considered meaningful for such a clamp study, since the algorithm of the 
clamp machine at Profil would stop GIR and introduce artificial variability for any BG elevation 
>5.5 mmol/L. In addition, blood glucose values were not shown, and lack of bioequivalence 
between identical doses of the two insulins was confirmed. Of note, the consistency of smooth 
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PD (GIR profile) over 24 h with Gla-300 reported in 2015 [23] was not confirmed in this 2017 
study, which showed decreased Gla-300 activity at 6–18 h post injection [51]. However, it 
should also be noted that this Heise et al review did not include the recent study by Bailey et 
al [49], therefore the full spectrum of available PK/PD evidence is not covered and its 
conclusions are indeed challenged by the findings of Bailey et al, which demonstrated that the 
within-day variability was significantly lower with Gla-300 than IDeg-100 at the 0.4 U/kg/day 
dose [49]. 
Clinical relevance of the PK/PD profiles of Gla-300 and IDeg 
Presently, only one phase 3 clinical trial of Gla-300 versus IDeg has been completed, the 
BRIGHT study [52]. This head-to-head trial in insulin naïve people with T2DM, uncontrolled on 
oral anti-hyperglycaemic drugs (with or without, glucagon-like peptide-1 receptor agonists) 
reported that Gla-300 and IDeg-100 provided similar glycaemic control accompanied by 
comparable hypoglycaemia during the full 6-month study period and 3–6 month maintenance 
period, and a lower incidence and rate of anytime (24 h) confirmed (3.9 mmol/L [≤70 mg/dL] 
and 3.0 mmol/L [<54 mg/dL]) hypoglycaemia with Gla-300 versus IDeg-100 during the initial 
3-month titration period [52]. Of note, the BRIGHT study also analysed glucose variability, 
both as within-day and day-to-day, on Gla-300 and IDeg treatment. Interestingly, no 
difference between Gla-300 and IDeg has been reported, either in the within-day or day-to-
day glucose variability during the 6-month study. Indirectly, these results, obtained with 
individual clinical, different and bioequivalent doses of the two insulins, are in contrast with 
the conclusions of Heise et al, 2017, that Gla-300 is 4-times more variable than IDeg [51]. CGM 
studies and real-life evidence would also greatly assist in identifying the potential clinical 
impact of subtle PK/PD differences between Gla-300 and IDeg.  
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Limitations of PK/PD studies 
There are known limitations to PK/PD studies utilising euglycaemic clamps to describe the 
time–action characteristics of insulin preparations, especially those with protraction actions. 
Between-study comparisons can be especially difficult owing to differences in criteria used to 
define the onset and end of insulin action. Different plasma concentrations of glucose and 
insulin at the start of the clamp (i.e. different methodologies in preparing subjects before the 
euglycaemic clamp), insulin dose used and the degree of insulin sensitivity can also all impact 
measures of treatment effect. The relevance of clamp studies is further lessened when healthy 
volunteers or those with T2DM are studied [56], because endogenous insulin secretion is a 
major confounding factor and buffers the PK/PD differences between basal insulins observed 
in T1DM. For these various reasons, studies should preferably be limited to individuals with 
T1DM; however, performing a euglycaemic clamp in individuals with T1DM is neither easy, 
nor is there a standardised and generally accepted procedure available. For example, with 
evening dosing, the subject has had lunch with a subcutaneous injection of rapid-acting insulin 
analogue, contrasting with morning dosing, which is preceded by an overnight insulin/glucose 
infusion regimen designed to address the lower insulin sensitivity at night and early morning 
(dawn phenomenon) [5]. There are also advantages and limitations to automated and manual 
clamps. Automated clamps make minute-to-minute blood glucose measurement using a 
glucose sensor, and an algorithm automatically adjusts the GIR [57]. The advantage is that the 
machine always uses the same algorithm, thereby eliminating the operator bias that may 
occur with manual clamps, but the problem is that GIR fluctuates artificially every minute 
because of imprecision of the glucose sensor [57]. Conversely, the manual clamp has the 
advantage of plasma glucose measurement with a reliable glucose analyser up to every 2.5 
minutes and results in a steady GIR over longer intervals compared with the automated clamp. 
Expertise in manual clamping improves the performance of the clamp, but the skills gained do 
not transfer to the automated technique, which cannot be regulated by the operator. 
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Interestingly, any head-to-head comparison between automated and manual clamps is 
currently not possible, as the company that produces and uses the device does not intend to 
commercialise it [58]. Recently, the importance of careful preparation of subjects prior to a 
clamp experiment has been emphasised, and the metabolic status over the five hours prior to 
clamp initiation (T0) has been presented in detail for the first time [6]. 
PD measurements of variability are confounded by insulin sensitivity, which varies according 
to time of day [5] and from day-to-day in individuals with and without diabetes, although this 
represents daily life. In contrast, PK measurements provide a clearer picture of variability in 
plasma INS following subcutaneous insulin injection, reliant on appropriate assay technology. 
As within-day glucose variability is a measure linked to the risk of hypoglycaemia seen in 
clinical practice [2,3] and can be studied using CGM [34], accurate measurement of short-term 
glycaemic variability is important. Given that PK measures of IDeg do not differentiate 
between the active free-form and the inactive albumin-bound form in plasma [37], this limits 
the usefulness of PK measures of variability for IDeg [54]. 
Conclusions 
PK/PD results from euglycaemic clamp studies comparing Gla-300 and Gla-100 concur in 
demonstrating that Gla-300 has a more stable and prolonged PK/PD profile compared with 
Gla-100 [23,28]. CGM studies, which provide more clinically relevant insights, also reach 
similar conclusions [33,34]. 
The EDITION clinical trial programme confirms that the improved PK/PD profile of Gla-300 
versus Gla-100 results in a reduced risk of nocturnal hypoglycaemic events as well as 
hypoglycaemic events occurring at any time in T2DM, while maintaining comparable 
glycaemic control [17,24,26,27,31,32]. In T1DM, hypoglycaemia was similar between Gla-300 
and Gla-100 [25], except for nocturnal conﬁrmed (≤3.9 mmol/L [≤70 mg/dL]) or severe 
hypoglycaemia in the first 8-weeks of the study which was lower with Gla-300 versus Gla-100 
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(risk ratio 0.69 [95% CI 0.53–0.91])[25]. While the EDITION programme did not demonstrate 
clear hypoglycaemia benefits in T1DM, a CGM study provided support for the lower glucose 
variability with Gla-300 (n=30) compared with Gla-100 (n=29), translating into a reduced risk 
of hypoglycaemia [34], thereby making dose titration safer whilst also allowing more flexibility 
in injection time. To fully demonstrate this clinical benefit, other types of studies are required, 
including observational studies that reflect real-life clinical practice. Future studies should 
maximise the new knowledge of PK/PD of Gla-300 used at clinical doses, and titrate Gla-300 
to prevent nocturnal hypoglycaemia while benefitting from a full 24-h basal insulin 
distribution. 
In T2DM, mean HbA1c reductions achieved with Gla-100, IDeg-100 or IDeg-200 were similar, 
which is unsurprising given the treat-to target study designs [39,44]. Gla-100, however, was 
associated with higher rates of nocturnal confirmed (<3.1 mmol/L [<56 mg/dL]) or severe 
hypoglycaemia, and severe hypoglycaemia, versus IDeg-100 [44]. However, this 
hypoglycaemia benefit with IDeg was not seen in a study comparing Gla-100 and IDeg-200, 
possibly due to the lower number of participants in this study [39]. Similarly, given the use of 
a treat-to-target study design, no difference was observed between Gla-100 and IDeg-100 
with respect to the lowering of HbA1c in T1DM, although the rate of nocturnal confirmed 
hypoglycaemia was higher with Gla-100 compared with IDeg-100 [47]. 
While both Gla-300 and IDeg have more stable and prolonged PK/PD profiles compared with 
the earlier basal insulin analogue, Gla-100, there have been conflicting results when the PK/PD 
profiles of the two second-generation basal insulins have been compared directly [49,51]. 
However, this may reflect differences in study methodologies and analyses. In addition to the 
inability to compare the pharmacokinetics of Gla-300 and IDeg, as previously discussed, it 
should also be noted that the euglycaemic clamp technique, when used to compare essentially 
similar long-acting insulin preparations, cannot be considered sufficiently sensitive to detect 
small pharmacodynamic differences (especially beyond 20 h post-dosing) because of the well-
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documented within- and between-day variability in insulin sensitivity.  To reach clear 
conclusions, direct head-to-head comparisons of Gla-300 and IDeg-100 or IDeg-200 in 
adequately powered PK/PD studies using standardised methodology are required, ensuring 
that the two insulins reach comparable glucose metabolic effects. 
Apart from the BRIGHT study in insulin-naïve people [52], there are currently no data from 
completed long-term clinical trials directly comparing Gla-300 and IDeg in other T2DM 
populations such as those on basal or basal-bolus insulin. However, a network meta-analysis 
suggests that they have comparable clinical benefit [59]. CGM technology would certainly help 
to confirm whether any PK/PD differences between Gla-300 and IDeg translate into clinically 
relevant glycaemic benefits. Pragmatic study designs, including observational approaches, 
may also be required to help elucidate any differences between these insulins in day-to-day 
clinical practice. 
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Figure Legends 
Figure 1. Steady-state INS profiles (A) and GIR profiles (B) in a euglycaemic clamp study 
comparing fixed dosing with Gla-300 and Gla-100 [23], and steady-state GIR profiles (C) in a 
euglycaemic clamp study comparing individually adjusted doses of Gla-300 and Gla-100 [6] 
 
Figure 1C: data are mean + SE. 
GIR, glucose infusion rate; Gla-100, insulin glargine 100 U/mL; Gla-300, insulin glargine 300 U/mL; INS, insulin 
concentration; LLOQ, lower limit of quantification 
Figure 1A and 1B: Reproduced with permission from Becker R.H., et al. New insulin glargine 300 Units.mL-1 provides 
a more even activity profile and prolonged glycaemic control at steady state compared with insulin glargine 100 
Units.mL-1. ©2015 by the American Diabetes Association®. Diabetes Care 2015;38(4):637–43. Reprinted with 
permission from the American Diabetes Association® 
 Figure 1C: Reproduced with permission from Porcellati F, et al. Pharmacokinetics, Pharmacodynamics, and 
Modulation of Hepatic Glucose Production With Insulin Glargine U-300 and Glargine U-100 at Steady State With 
Individualized Clinical Doses in Type 1 Diabetes. Diabetes Care. 2018 Oct 10. doi: 10.2337/dc18-0706. ©2018 by 
the American Diabetes Association®. Diabetes Care 2018 October. Reprinted with permission from the American 
Diabetes Association® 
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Figure 2. GIR profiles (A), percentages of 6-h fractions of the total 24-h glucodynamic activity 
(GIR-AUC0–24) (B), and mean serum INS profiles with Gla-300 (C) and IDeg-100 (D) at the 0.4 
U/kg/day dose level in steady state [49] 
 
AUC, area under the curve; GIR, glucose infusion rate; Gla-300, insulin glargine 300 U/mL; IDeg-100, insulin 
degludec 100 U/mL; INS, insulin concentration; LLOQ, lower limit of quantification 
Reproduced from Bailey TS, Pettus J, Roussel R, Schmider W, Maroccia M, Nassr N, Klein O, Bolli GB, Dahmen R. 
Morning administration of 0.4 U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour 
pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 
diabetes. Diabetes Metab 2018;44(1):15–21. Copyright ©2017 The Authors. Published by Elsevier Masson SAS. All 
rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/  
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Figure 3. Steady-state 24-h insulin concentration-time profiles of IDeg-100 (A) and Gla-100 
(B) at 3 fixed dose levels in T1DM [37]  
 
IDeg, insulin degludec; IDeg-100, insulin degludec 100 U/mL; Gla, insulin glargine; Gla-100, insulin glargine 100 
U/mL; T1DM, type 1 diabetes 
Reproduced with permission from Heise T., et al., Comparison of the pharmacokinetic and pharmacodynamic 
profiles of insulin degludec and insulin glargine. Expert Opin Drug Metab Toxicol 2015;11(8):1193–201 
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Figure 4. Glycaemic excursions above the clamp target of 5.5 mmol/L (100 mg/dL) in studies 
of Gla-300 vs IDeg: (A) Individual Gla-300 vs IDeg-200 profiles, Heise et al. 2017 [51] and (B) 
mean Gla-300 vs IDeg-100 profiles, Bailey et al. 2017 [49] 
 
(A) Red dotted line=mean blood glucose in each treatment group. IDeg-100, insulin degludec 100 U/mL; IDeg-200, 
insulin degludec 200 U/mL; Gla-300, insulin glargine 300 U/mL 
Figure 4A: Reproduced with permission from Heise T., et al. Insulin degludec: Lower day-to-day and within-day 
variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabetes 
Obes Metab 2017;19(7):1032–1039. Copyright ©2017 The Authors. Diabetes, Obesity and Metabolism published 
by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/. Figure 4B: Reproduced from Bailey TS, 
Pettus J, Roussel R, Schmider W, Maroccia M, Nassr N, Klein O, Bolli GB, Dahmen R. Morning administration of 0.4 
U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even 
pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes. Diabetes Metab 
2018;44(1):15–21. Copyright ©2017 The Authors. Published by Elsevier Masson SAS. All rights reserved. 
https://creativecommons.org/licenses/by-nc-nd/4.0/ 
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Table 
 
Table 1. Key findings described in euglycaemic clamp studies with Gla-300, Gla-100 and IDeg (100 and 200 U/mL) 
 
Study Mean prior 
basal 
(prandial) 
insulin dose 
(U/kg/day) 
Gla-300 
dose, 
U/kg/day 
(timing)  
Gla-100 
dose, 
U/kg/day 
(timing) 
IDeg dose, 
U/kg/day 
(timing) 
Clamp  Main study conclusions 
Porcellati et al, 2015[5] 
10 participants with T2DM 
 
0.27 (1.19) 
morning; 
0.30 (0.30) 
evening 
N/A 0.4 
(morning 
[n=5] or 
evening 
[n=5]) 
N/A 24-h clamp 
following 9 
days of 
morning or 
evening 
dosing 
• The 24-h glucose infusion rate area under the curve 
(GIR-AUC0–24h) was similar with evening and morning 
dosing (1,058±571 and 995±691 mg/kg [p=0.503]) 
• GIR-AUC0–12h was lower with evening versus morning 
dosing (357±244 vs. 593±374 mg/kg [p=0.004]), 
whereas GIR-AUC12–24h was lower for morning dosing 
(700±396 vs. 403±343 mg/kg [p=0.002]) 
Becker et al, 2015[23] 
30 participants with T1DM. 
Cohort 1: Mean age 44.9 years, BMI 25.9 
kg/m2, duration of diabetes 26.9 years, 
HbA1c 7.8 % (62 mmol/mol); Cohort 2: 
Mean age 41.0 years, BMI 24.8 kg/m2, 
duration of diabetes 26.5 years, HbA1c 
8.0 % (64 mmol/mol) 
 
Inclusion criteria: males/females (18–65 
years), BMI 18–30 kg/m2, T1DM ≥1 
years, stable insulin regimen for ≥2 
months, total daily insulin dose <1.2 
U/kg, HbA1c ≤9.0 %  
Cohort 1: 
0.30 (0.29); 
Cohort 2: 
0.35 (0.34) 
0.4  
(evening) 
0.4 
(evening) 
 
N/A 36-h clamp 
following 
Day 8 dose 
• Steady-state INS and GIR profiles for Gla-300 were more 
constant and prolonged and more evenly distributed 
over 24 h versus Gla-100 
• Smaller swing in steady-state INS profile over 24 h of <1 
with Gla-300 (median swing [IQR]: 0.8; [0.6–1.0]) as 
compared with Gla-100 (median swing [IQR]: 1.8; [1.3–
2.3]) at 0.4 U/kg/day 
• Euglycaemia (≤5.8 mmol/L or ≤105 mg/dL) was 
maintained for ~5 h longer (median 30 h) with Gla-300 
versus Gla-100 
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Heise et al, 2015[37] 
66 participants with T1DM 
Mean age 36.9 years, BMI 24.9 kg/m2, 
duration of diabetes 17.6 years, HbA1c 
8.1 % (65 mmol/mol) 
 
Inclusion criteria: males/females (18–
65 years), BMI 18–28 kg/m2, T1DM ≥1 
year, multiple daily insulin injections 
for ≥12 months, total daily insulin 
dose <1.2 U/kg, daily basal insulin 
≥0.2 U/kg, HbA1c ≤10.0 % 
Not reported  N/A 0.4, 0.6 or 
0.8 
(evening) 
IDeg-100 at 
0.4, 0.6 or 
0.8 
(evening) 
42-h clamp 
in steady 
state  
• Mean 24-h GIR profiles were flatter and more stable for 
all doses of IDeg-100 versus Gla-100 
• Individual serum INS fluctuated less around the 
individual mean levels (relative fluctuation at 0.4, 0.6 
and 0.8 U/kg/day) with IDeg (14%, 13% and 14%, 
respectively) than with Gla-100 (22%, 21% and 24%, 
respectively) 
• Relative fluctuation in GIR (AUCfGIR,t,SS; at 0.4, 0.6 and 0.8 
U/kg/day) was lower for IDeg (0.25, 0.37 and 0.38 
mg/kg/min, respectively) than for Gla-100 (0.39, 0.54 
and 0.73 mg/kg/min, respectively) at steady state  
Heise et al, 2012[36] 
54 participants with T1DM 
Mean Gla-100/IDeg age 36/40 years, 
BMI 24.8/24.6 kg/m2, HbA1c 7.5/7.8 % 
(58.5/61.7 mmol/mol) 
 
Inclusion criteria: males/females (18–
65 years), BMI 18–28 kg/m2, T1DM ≥1 
year, multiple daily insulin injections 
for ≥12 months, total daily insulin 
dose <1.2 U/kg, daily basal insulin 
≥0.2 U/kg, HbA1c ≤10.0 % 
Not reported N/A 0.4 
(evening) 
IDeg-100 
0.4 
(evening) 
24-h 
clamps on 
Days 6, 9 
and 12 of a  
12-day 
treatment 
period  
• Relative day-to-day variability in glucose-lowering effect 
was lower for IDeg-100 than for Gla-100 for total 
metabolic effect (AUCGIR,0–24h,SS) with a CV of 20% versus 
82%, respectively  
• Lower within-subject variability with IDeg versus Gla-100 
was consistent over time: AUCGIR,0–2h,SS CVs, 33% and 
60%, respectively; AUCGIR,10–12h,SS CVs, 32% and 155%, 
respectively; and AUCGIR,22–24h,SS CVs, 33% and 115%, 
respectively 
• The day-to-day variability in the GIR fluctuations around 
the mean during the 24-h dosing interval at steady state 
(AUCFGIR,0–24h,SS) was significantly lower for IDeg-100 (CV 
31%) than for Gla-100 (CV 73%), (p<0.0001) 
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Becker et al, 2015[29] 
50 participants with T1DM 
Mean age 42.1 years, mean BMI 25.4 
kg/m2 
 
Inclusion criteria: males/females (18–
64 years), T1DM ≥1 year, total insulin 
dose <1.2 U/kg/day, basal insulin dose 
≥0.2 U/kg/day 
0.35  
(prandial dose 
not reported) 
0.4 with and 
without 
polysorbate-
20 (evening) 
N/A N/A 24-h clamp 
on Day 6 
• Gla-300 provides predictable, evenly distributed 
steady-state 24-h coverage with low fluctuation and 
high reproducibility in insulin exposure 
• Within-subject variability of Gla-300 (i.e. day-to-day 
variability) for INS-AUC0–24 and GIR-AUC0–24 were 17.4% 
(95% CI: 15–21) and 34.8% (95% CI: 30–42), 
respectively 
• Diurnal fluctuation in exposure (within-day variability) 
was low, with a median PTR of 1.8 [IQR 1.5–2.1]; 
correspondingly, the swing degree of fluctuation 
[median 0.8; IQR 0.5–1.1] and the peak-to-trough 
fluctuation [median 0.6; IQR 0.4–0.7] were <1 
 
Bailey et al, 2017[49] 
48 participants with T1DM 
Cohort 1: Mean age 43.7 years, BMI 
25.4 kg/m2, HbA1c 7.4 % (57.4 
mmol/mol), diabetes duration 23.0 
years; Cohort 2: Mean age 41.0 years, 
BMI 26.0 kg/m2, HbA1c 7.2 % (57.4 
mmol/mol), diabetes duration 23.3 
years 
 
Inclusion criteria: males/females (18–
64 years), T1DM >1 year, stable 
insulin regimen with total daily insulin 
dose <1.2 U/kg, BMI 18–30 kg/m2, 
HbA1c ≤9.0 %  
Cohort 1: 0.34 
(0.33); Cohort 
2: 0.30 (0.29) 
0.4 
(morning) 
 
0.6 
(morning) 
N/A IDeg-100  
0.4 
(morning) 
30-h clamp 
following 
Day 8 dose 
• Within-day variability of smoothed GIR (GIR-smFL0–24) 
was 20% lower with Gla-300 than IDeg-100 (p=0.047) 
with the mean (SD) fluctuation of the smoothed GIR 
(GIRsmFL0–24) being 0.38 (0.17) mg/min/kg with Gla-
300 versus 0.46 (0.19) mg/min/kg with IDeg-100 
• Trend towards GIR-smFL0–24 being lower for Gla-300 at 
the 0.6 U/kg/d dose 
• More stable GIR profile for Gla-300 versus IDeg-100 
• More evenly distributed insulin exposure over 24 h 
with Gla-300 versus IDeg-100 
• Relative 24-h fluctuation in insulin exposure was 40% 
for Gla-300 and 46% for IDeg-100 at the 0.4 U/kg dose 
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Heise et al, 2017 [51] 
57 participants with T1DM  
Mean age 45.1 years, BMI 25.6 kg/m2, 
HbA1c 7.3 % (56.3 mmol/mol) and 
diabetes duration 21.9 years 
 
Inclusion criteria: Males/females (18–
64 years), T1DM ≥1 year, stable 
insulin regimen with total daily insulin 
<1.2 U/kg/day and daily basal insulin 
≥0.2 U/kg, BMI 18.5–29.0 kg/m2, 
HbA1c ≤9.0 % 
0.32  
(prandial dose  
not reported) 
0.4 (evening) N/A IDeg-200  
0.4 (evening) 
24-h 
clamps on 
Days 6, 9 
and 12 of 
a 12-day 
treatment 
period 
• “Four-times less day-to-day PD variability with IDeg-200 
versus Gla-300”: relative day-to-day variability (in CV %) 
was 33% for IDeg and 67% for Gla-300; given as variance 
ratio: 3.70, 95% CI [2.42–5.67], p<0.0001) 
• 37% lower relative within-day variability with IDeg-200 
versus Gla-300 (post hoc analysis, absolute within-day 
variability as shown in previous studies [36] not 
presented here) 
Porcellati et al, 2018 [6] 
18 participants with T1DM 
Mean age 40 years, T1DM duration 26 
years, BMI 23.4 kg/m2, HbA1c 7.19 % 
(55 mmol/mol) 
 
Inclusion criteria: Males/females aged 
between 18 and 65 years, with 
disease duration ≥5 years, 
HbA1c between 6.5 % (48 mmol/mol) 
and 8.5 % (69 mmol/mol), and BMI 
>20 to ≤27 kg/m2 
0.30 (0.29) 0.35 
(evening) 
0.28 
(evening) 
N/A 24-h 
clamps 
after 3 
months of 
dosing 
• Individualised, clinical doses of Gla-300 and Gla-100 
resulted in a similar euglycaemic potential under steady-
state conditions 
• However, Gla-300 exhibited a more stable profile, with 
lower variability and more physiological modulation of 
endogenous hepatic glucose production compared with 
Gla-100 
AUC, area under the curve; BG, blood glucose; BMI, body mass index; CI, confidence interval; CV, coefficient of variation; GIR, glucose infusion rate; Gla-100, insulin glargine 100 U/mL; Gla-300, 
insulin glargine 300 U/mL; IDeg, insulin degludec; IDeg-100, insulin degludec 100 U/mL; IDeg-200, insulin degludec 200 U/mL; INS, insulin concentration; IQR, interquartile range; N/A, not 
applicable; PD, pharmacodynamic; PTR, peak-to-trough ratio; T1DM, type 1 diabetes 
